Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Last trade$27.18
Day change-$0.62 (-2.23%)
Day range$26.62 – $28.16
Volume506,552
Market cap$3.57B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.57B
Price / earnings
—
Price / book
4.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-19×
Profitability
Earnings per share
-$1.27
Return on assets
-20.74%
Return on equity
-21.65%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
26.81×
Quick ratio
26.81×
Cash ratio
8.27×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$130.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AMLX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
—
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
—
Selling, general and administrative
$21.31M
$21.93M
$16.17M
$15.39M
$16.17M
$15.64M
$15.68M
—
Research and development
$28.35M
$23.77M
$27.61M
$21.21M
$19.86M
$27.22M
$22.12M
—
Total operating expenses
$49.66M
$45.69M
$43.78M
$36.61M
$36.03M
$42.86M
$37.8M
—
Operating income
-$49.66M
-$45.69M
-$43.78M
-$36.61M
-$36.03M
-$42.86M
-$37.8M
—
Interest expense
$0
$0
$0
$0
$0
$0
$0
—
Income before taxes
-$45.49M
-$43.42M
-$41.28M
-$32.95M
-$34.39M
-$41.44M
-$35.91M
—
Income taxes
$0
$0
$0
$46K
$0
$0
$0
—
Net income
-$45.49M
-$43.42M
-$41.28M
-$33M
-$34.39M
-$41.44M
-$35.91M
—
Net income attributable to common shareholders
-$45.49M
-$43.42M
-$41.28M
-$33M
-$34.39M
-$41.44M
-$35.91M
—
EBITDA
-$49.63M
-$45.65M
-$43.68M
-$36.5M
-$35.91M
-$42.72M
-$37.65M
$160K
Basic earnings per share
-$0.38
-$0.39
-$0.37
-$0.30
-$0.37
-$0.46
-$0.42
—
Diluted earnings per share
-$0.38
-$0.39
-$0.37
-$0.30
-$0.37
-$0.46
-$0.42
—
Recent news
Company coverage with links to the original publishers.
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022 to November 2023 period.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022-2023.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 28, 2018
$0.4197
Apr 2, 2018
recurring
Dec 28, 2017
$0.3556
Jan 2, 2018
recurring
Sep 28, 2017
$0.2408
Oct 2, 2017
unknown
Stock splits
Historical share-structure events and their execution dates.